| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-3223(91)90209-5 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:0006322391902095?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:0006322391902095?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1848113 |
| P2093 | author name string | J. E. Kleinman | |
| M. F. Casanova | |||
| E. B. De Souza | |||
| E. D. London | |||
| A. D. Weissman | |||
| P2860 | cites work | Protein measurement with the Folin phenol reagent | Q20900776 |
| Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice | Q28342521 | ||
| LIGAND: A versatile computerized approach for characterization of ligand-binding systems | Q29547346 | ||
| Schizophrenia and the frontal lobe | Q38201347 | ||
| Dopamine receptors and the dopamine hypothesis of schizophrenia | Q39471744 | ||
| Cerebellar pathology in schizophrenia--cause or consequence? | Q40328600 | ||
| Characterization of specific sigma opiate/phencyclidine (PCP)-binding sites in the human brain. | Q41452704 | ||
| Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs | Q41773246 | ||
| Selective sigma receptor agonist and antagonist affect dopamine neuronal activity | Q42190130 | ||
| A postmortem study of the effect of chronic opiate abuse on psychotomimetic binding sites of human frontal cortex | Q42200097 | ||
| Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine | Q42205824 | ||
| Phencyclidine-induced psychosis | Q43637366 | ||
| An endogenous ligand for the sigma opioid binding site | Q44343561 | ||
| Endogenous ligands for sigma opioid receptors in the brain ("sigmaphin"): evidence from binding assays | Q44346851 | ||
| Chronic haloperidol treatment up-regulates rat brain PCP receptors | Q44821781 | ||
| Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder | Q45297275 | ||
| Autoradiographic distribution of non-dopaminergic binding sites labeled by [3H]haloperidol in rat brain | Q45351501 | ||
| Pharmacological characteristics and distributions of sigma- and phencyclidine receptors in the animal kingdom | Q46166588 | ||
| Alterations in local cerebral glucose utilization induced by phencyclidine | Q48177017 | ||
| High correlation between the localization of [3H]TCP binding and NMDA receptors | Q48355489 | ||
| Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage | Q48465361 | ||
| The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity | Q48622361 | ||
| An anatomy of schizophrenia? | Q48642309 | ||
| [3H]TCP: a new tool with high affinity for the PCP receptor in rat brain | Q48713443 | ||
| Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. | Q50802287 | ||
| Respiratory and subjective effects of dand l-pentazocine. | Q51340760 | ||
| (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients | Q57781184 | ||
| Gross Pathology of the Cerebellum in Patients Diagnosed and Treated as Functional Psychiatric Disorders | Q67019409 | ||
| Clinical management of the phencyclidine psychosis | Q67832361 | ||
| Characterization of L-glutamate action on the release of endogenous dopamine from the rat caudate-putamen | Q69367663 | ||
| Regulation of sigma-receptors: high- and low-affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-Di(2-tolyl)guanidine | Q69372635 | ||
| Prenatal developmental disturbances in the limbic allocortex in schizophrenics | Q69518888 | ||
| Sigma receptors negatively modulate agonist-stimulated phosphoinositide metabolism in rat brain | Q69835434 | ||
| Sigma and PCP receptors in human frontal cortex membranes | Q69850247 | ||
| Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI) | Q69924684 | ||
| Activation of the A10 mesolimbic system by the sigma-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic | Q69925850 | ||
| Novel antipsychotic drugs share high affinity for sigma receptors | Q69930877 | ||
| Schizoaffective psychosis. I. Comparative long-term outcome | Q70326603 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 41-54 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia | |
| Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia | |||
| P478 | volume | 29 |
| Q41581748 | A two-process theory of schizophrenia: evidence from studies in post-mortem brain |
| Q48922742 | Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding |
| Q48241999 | An increase of sigma receptors in the aged monkey brain |
| Q77700428 | Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia |
| Q37559277 | Asymmetric Synthesis of Spirocyclic 2-Benzopyrans for Positron Emission Tomography of σ1 Receptors in the Brain |
| Q41289597 | Basis of the antiseizure action of phenytoin |
| Q58732614 | Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor |
| Q33921280 | Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry |
| Q38244707 | Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography |
| Q41389291 | Dopaminergic sensitization: implications for the pathogenesis of schizophrenia |
| Q78228755 | Electrophysiological effects of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons |
| Q34007801 | Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor |
| Q28184848 | Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice |
| Q48245172 | Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. |
| Q73195199 | In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET |
| Q73428054 | In vivo regulation of serotonin 5-HT2A receptors in rat brain by subchronic administration of sigma receptor ligand NE-100 |
| Q89723642 | Less NMDA Receptor Binding in Dorsolateral Prefrontal Cortex and Anterior Cingulate Cortex Associated with Reported Early Life Adversity but Not Suicide |
| Q48915313 | Mapping of CNS sigma(1) receptors in the conscious monkey: preliminary PET study with [(11)C]SA4503. |
| Q30428213 | Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment |
| Q43774253 | Multiple pathways of sigma(1) receptor ligand uptakes into primary cultured neuronal cells |
| Q73294148 | Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia |
| Q47951456 | Neuropeptide Y-mediated enhancement of NMDA-stimulated [3H]dopamine release from rat prefrontal cortex is reversed by sigma1 receptor antagonists |
| Q40932666 | Neurotransmitter systems in schizophrenia. |
| Q40524584 | New approaches to the drug treatment of schizophrenia |
| Q24792449 | No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies |
| Q48544128 | Pharmacological comparison of the sigma recognition site labelled by [3H]haloperidol in human and rat cerebellum |
| Q36848319 | Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia |
| Q44494959 | Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [(18)F]FPS. |
| Q44438932 | Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats |
| Q74147621 | Repeated haloperidol treatment decreases sigma(1) receptor binding but does not affect its mRNA levels in the guinea pig or rat brain |
| Q34046060 | Reviewing the ketamine model for schizophrenia |
| Q67487043 | Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization |
| Q48429016 | Sigma receptors in schizophrenic cerebral cortices |
| Q28266963 | Sigma receptors: biology and therapeutic potential |
| Q44454363 | Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands |
| Q47756273 | Structure-Activity Relationships within a Series of σ1 and σ2 Receptor Ligands: Identification of a σ2 Receptor Agonist (BS148) with Selective Toxicity against Metastatic Melanoma. |
| Q51076938 | Synthesis, σ receptor affinity, and pharmacological evaluation of 5-phenylsulfanyl- and 5-benzyl-substituted tetrahydro-2-benzazepines. |
| Q34795242 | Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders |
| Q38262682 | The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders |
| Q51750311 | The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. |
| Q50134834 | The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm |
| Q73093995 | The involvement of sigma receptors in the choice reaction performance deficits induced by phencyclidine |
| Q36653400 | The sigma-1 receptor: roles in neuronal plasticity and disease |
| Q48656155 | Uncompetitive inhibition of [3H]1,3-di-o-tolyl-guanidine-defined sigma binding sites by desipramine, propranolol and alprenolol in rat brain |
Search more.